Tesamorelin Research

Tesamorelin is the only compound in this group that verifiably holds a therapeutic marketing authorization anywhere, which makes it both the best documented and the most easily misread. An approval is narrow by design, and this one covers one molecule in one patient population. This article reports what the literature and the primary regulatory record establish, not outcomes anyone should expect.

What tesamorelin is

Tesamorelin is one defined molecule rather than a marketing name. It is a synthetic analogue of human growth hormone releasing factor, GRF(1-44), bearing a trans-3-hexenoyl group on the N-terminus and amidated at the C-terminus.^[1] PubChem lists it as CID 16137828 under CAS 218949-48-5, formula C221H366N72O67S, average mass 5136.^[1] It acts at the pituitary GHRH receptor, raising endogenous growth hormone and, downstream, IGF-1.^[1]

That receptor is shared with CJC-1295 with DAC and with nothing else here, since the ghrelin-receptor and IGF-1 compounds act elsewhere. Research-grade tesamorelin is bulk material, a different regulatory object from an approved finished medicine.

The approval, stated exactly

FDA approved tesamorelin on 10 November 2010 under application 022505, as a Type 1 new molecular entity.^[2] The approved indication, quoted from the approval letter, is the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.^[2] The approval is current, not historical. The most recent supplement was approved on 25 March 2025, and two finished products remain in prescription marketing status.^[3][4] The prescribing information carries an effective date of 29 July 2026.^[5]

One further regulatory fact is routinely misdated. The application was deemed to be a license on 23 March 2020 under the Biologics Price Competition and Innovation Act. That transition is documented in a supplement approval letter dated 2024, not 2020.^[6]

What the approval does not cover

The approval belongs to the molecule tesamorelin and to one indication. It is not a family credential and must never be written as one. The eight compounds beside it in this group are CJC-1295 with DAC, GHRP-2, GHRP-6, hexarelin, HGH fragment 176-191, MGF, IGF-1 DES and IGF-1 LR3. Approved for one HIV-related indication is not the same as approved for what this catalogue's readers are interested in. No agency has approved tesamorelin for body composition, athletic, anti-aging or general fat-loss use, and no indication outside HIV-associated lipodystrophy has been approved for it anywhere.^[2][5] ClinicalTrials.gov also carries a terminated phase 2 trial in COPD with muscle wasting, stopped for a stated non-safety reason with three participants enrolled.^[7]

The approval is also not global. Tesamorelin never obtained a European marketing authorization, because the applicant withdrew the application on 21 June 2012 while it was under CHMP review.^[8] No refusal decision was ever issued, and the committee's position at withdrawal was explicitly provisional.^[8] That position was that the benefits did not outweigh the risks, on concerns including IGF-1 elevation and absent long-term safety data.^[8]

What the human trials found

Two multicenter randomized placebo-controlled phase 3 trials in humans enrolled 412 and 404 patients with HIV-associated abdominal fat accumulation.^[9][10] In the first, visceral adipose tissue fell 15.2% against a 5.0% rise on placebo over 26 weeks, and IGF-1 rose 81.0%.^[9] More patients on tesamorelin than on placebo withdrew because of an adverse event.^[9] A pooled analysis of both trials, 806 randomized, gave a treatment effect of -15.4% on visceral fat with no significant change in subcutaneous fat.^[11] The primary endpoints across this program are imaging surrogates, CT-measured abdominal fat, not clinical outcomes.^[9][10] All three papers were manufacturer-sponsored with sponsor-affiliated co-authors.

The human effect does not survive withdrawal. In the 26-week extension phase, giving 52 weeks of total exposure, the reduction held during treatment but reaccumulated on discontinuation.^[12] The authors concluded the effects do not last beyond treatment.^[12]

Independent NIH-funded human trials reduced liver fat as well as visceral fat, which is not an approved indication.^[13][14] That group discloses consulting relationships with the manufacturer in related work. A six-month randomized phase 2 trial in 73 people found no significant cognitive difference, p=0.673, and concluded there was no clear benefit.^[15] A 2026 meta-analysis of four randomized trials in 909 patients gave a visceral fat mean difference of -21.47 cm2.^[16] Its discontinuation risk ratio of 2.25 did not reach significance.^[16]

What the label itself constrains

An approval is not a clean bill of health, and this label says so itself. Its Limitations of Use state that long-term cardiovascular safety has not been established, and that it is not indicated for weight-loss management because it is weight neutral.^[5] It is contraindicated in active malignancy, in pregnancy, and in disruption of the hypothalamic-pituitary axis.^[5]

The labeled warnings run downstream of the IGF-1 rise, and include increased risk of neoplasms, fluid retention, and glucose intolerance or new diabetes.^[5] At 26 weeks, 47% of treated patients exceeded 2 standard deviation scores for IGF-1 and 36% exceeded 3.^[5] HbA1c reached 6.5% or above in 5% of treated patients against 1% on placebo.^[5]

In animals, lifetime carcinogenicity studies were never conducted, and rats given the compound during organogenesis produced offspring with hydrocephaly.^[17] That is an untested endpoint beside a precautionary warning, not a demonstration of harm.

FDA did not treat the safety picture as settled at approval, and the 2010 letter imposed a mandated 10-year observational study and a randomized retinopathy trial.^[18] Both registered studies are recorded as terminated, with no results posted and no stated reason.^[19] Whether FDA later released or modified those requirements is not established in the public record.

Duration is not shared across GHRH analogues

This is the inference most likely to be drawn without anyone writing it. Tesamorelin and CJC-1295 with DAC bind the same receptor, and only one of them has ever been approved. Sharing a receptor transfers nothing else, and the human pharmacokinetics show how far apart the two sit.

Tesamorelin's mean elimination half-life on the approved label is formulation-specific: 8 minutes for one formulation and 11 minutes for the other.^[20] It was dosed daily in every pivotal trial and on the label.^[11] CJC-1295 with DAC has an estimated human half-life of 5.8 to 8.1 days, and a single dose raised trough growth hormone 7.5-fold.^[21][22] In rats its maleimide group bound covalently to albumin, which is the proposed explanation for that duration rather than a demonstrated one.^[23]

Same receptor, exposures orders of magnitude apart in duration. GHRH analogue names a receptor target, not a duration of action.

IGF-1 evidence, and where it applies

Tesamorelin raises IGF-1 in people, measurably and by large margins, so the human IGF-1 epidemiology is relevant on this page.^[5][9] It is not relevant to compounds never shown to raise IGF-1 in a human, and it should not be carried onto them. That excludes MGF, IGF-1 DES, IGF-1 LR3 and the 176-191 fragment, none of which has been given to a person in any published study.

Higher circulating IGF-1 in humans is associated with prostate, breast and colorectal cancer across large prospective cohorts.^[24][25][26] The same UK Biobank analysis found reduced risk of ovarian and liver cancer.^[26]

Two caveats attach to all of it. These are prediagnostic endogenous differences in IGF-1 within the normal range. They are not measurements of what an administered GHRH analogue does.

One reported approval that is not comparable

A second approval story in this family needs care. GHRP-2, under the name pralmorelin, is reported to have been approved in Japan as a diagnostic agent for pituitary function testing.^[27] That report traces to a 2004 commercial pipeline profile recording the approval as pending, and it is unverified against any primary regulator.^[27] A diagnostic provocative-test approval is categorically different from a therapeutic one, and not comparable to tesamorelin's.

What this record supports

The honest contrast is not that tesamorelin works and the others might too. It is that tesamorelin is the only one of the nine that has been through the process that would let anyone know. Even for tesamorelin, the label leaves long-term cardiovascular safety unestablished, carcinogenicity testing was never done, and the mandated safety studies were terminated without results.

As of the 2026 Prohibited List, tesamorelin is prohibited at all times under Section S2 of the World Anti-Doping Agency list.^[28] Research material is supplied for laboratory research use only and is not for human consumption.

Frequently Asked Questions

Is tesamorelin FDA approved?

Yes, and the scope is narrow. FDA approved it on 10 November 2010 under application 022505, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and that approval is still in force.^[2][5] It has never been approved for body composition, athletic, anti-aging or general fat-loss use, and no indication outside HIV-associated lipodystrophy has been approved anywhere.^[2][5] It also never obtained a European marketing authorization, because the applicant withdrew the application while it was under CHMP review.^[8]

Does the approval say anything about the other GHRH analogues or secretagogues?

No. The approval belongs to the molecule tesamorelin and to one indication, and it is not a family credential. Tesamorelin and CJC-1295 with DAC share the GHRH receptor, but tesamorelin's human half-life is 8 to 11 minutes while CJC-1295 with DAC's is 5.8 to 8.1 days.^[20][21] GHRH analogue names a receptor target, not a duration of action.

What is the strongest human evidence, and what are its limits?

Two placebo-controlled phase 3 trials totaling 806 randomized patients, a 26-week extension, independent NIH-funded randomized trials, and a 2026 meta-analysis of four trials.^{[9][10][11][12][16]} All of it is in people with HIV-associated lipodystrophy or related HIV conditions, and the primary endpoints are imaging surrogates rather than clinical outcomes. The pivotal program was manufacturer-sponsored, and the visceral fat effect reverses once the compound is stopped.^[12]

Does the IGF-1 and cancer literature apply to tesamorelin?

It is relevant here, because tesamorelin has been shown to raise IGF-1 substantially in humans.^[5][9] The epidemiology itself measures prediagnostic endogenous IGF-1 differences within the normal range, not administered analogues, and the same large cohort found reduced risk at some sites.^[24][26] It does not transfer to compounds never shown to raise IGF-1 in a person.

References

1. 1

   PubChem Compound record CID 16137828 (CAS 218949-48-5), National Library of Medicine; corroborated by Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071-1091. PMID 21668043.
2. 2

   US Food and Drug Administration, Center for Drug Evaluation and Research. NDA approval letter, application 022505, 10 November 2010 (Reference ID 2863003).
3. 3

   US Food and Drug Administration. Supplement approval letter, BLA 022505/S-020, approved 25 March 2025 (Reference ID 5557578).
4. 4

   openFDA drug/ndc endpoint, generic_name tesamorelin, application_number BLA022505; queried 27 August 2026. Two finished-product records, neither carrying a marketing end date.
5. 5

   US Food and Drug Administration. Approved prescribing information (Structured Product Labeling), BLA 022505, effective 29 July 2026; retrieved via openFDA drug/label.
6. 6

   US Food and Drug Administration. Supplement approval letter, BLA 022505/S-018, approved 27 February 2024 (Reference ID 5336239), recording the 23 March 2020 deemed-BLA transition.
7. 7

   ClinicalTrials.gov record NCT01388920 (org ID TH9507-CTR-1025), phase 2 in COPD with muscle wasting; terminated with 3 participants enrolled, for a stated non-safety corporate reason. Retrieved via API v2, 27 August 2026.
8. 8

   European Medicines Agency / Committee for Medicinal Products for Human Use. Withdrawal of the marketing authorisation application for Egrifta (tesamorelin), applicant Ferrer Internacional S.A.; questions-and-answers document EMA/CHMP/475021/2012, 12 July 2012. Filed by EMA under withdrawn applications.
9. 9

   Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID 18057338.
10. 10

    Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. PMID 20101189.
11. 11

    Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. PMID 20554713.
12. 12

    Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. PMID 18690162.
13. 13

    Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. PMID 25038357.
14. 14

    Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID 31611038.
15. 15

    Ellis RJ, Vaida F, Hu K, Dube M, Henry B, Chow F, et al. Effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity. J Infect Dis. 2025;231(5):1230-1238. PMID 39813152. Registered as NCT02572323; a randomized phase 2 trial with a standard-of-care comparator.
16. 16

    Ditta AM, Naeem RM, Sami MM, Abdul Rafey M, Ali H, Amjad MW, et al. Efficacy and safety of tesamorelin in people living with HIV (PLWH) with lipodystrophy: a systematic review and meta-analysis. J Int Assoc Provid AIDS Care. 2026;25:23259582261475549. PMID 42538058.
17. 17

    US Food and Drug Administration. Approved prescribing information, BLA 022505, sections 8.1, 8.4 and 13.1 (pregnancy, pediatric use, carcinogenesis), effective 29 July 2026.
18. 18

    US Food and Drug Administration. NDA approval letter, application 022505, postmarketing requirements 1708-1, 1708-2 and 1708-3, 10 November 2010 (Reference ID 2863003).
19. 19

    ClinicalTrials.gov records NCT01579695 (n=391 actual) and NCT01591902 (n=129 actual), sponsor Theratechnologies; both terminated, no results posted, no reason stated. Retrieved via API v2, 27 August 2026.
20. 20

    US Food and Drug Administration. Approved prescribing information, BLA 022505, section 12.3. The two current labels give a mean elimination half-life of 8 minutes and 11 minutes for the two approved formulations.
21. 21

    Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683.
22. 22

    Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID 17018654.
23. 23

    Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID 15817669. Rat study; the originating paper for the drug affinity complex construct.
24. 24

    Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346-1353. PMID 15110491.
25. 25

    Endogenous Hormones and Breast Cancer Collaborative Group; Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530-542. PMID 20472501.
26. 26

    Knuppel A, Fensom GK, Watts EL, Gunter MJ, Murphy N, Papier K, et al. Circulating insulin-like growth factor-I concentrations and risk of 30 cancers: prospective analyses in UK Biobank. Cancer Res. 2020;80(18):4014-4021. PMID 32709735.
27. 27

    Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs R D. 2004;5(4):236-239. PMID 15230633. A commercial drug-pipeline profile, not a regulatory document. Validation study: Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Kato Y, for the KP-102 Study Group. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27. PMID 17609397.
28. 28

    World Anti-Doping Agency. The 2026 Prohibited List, Section S2 (peptide hormones, growth factors, related substances and mimetics), in force 1 January 2026.